Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.

Hopley, Charles W; Kavanagh, Sarah; Patel, Manesh R; Ostrom, Cara; Baumgartner, Iris; Berger, Jeffrey S; Blomster, Juuso I; Fowkes, F Gerry R; Jones, W Schuyler; Katona, Brian G; Mahaffey, Kenneth W; Norgren, Lars; Rockhold, Frank W; Hiatt, William R (2019). Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vascular medicine, 24(5), pp. 422-430. Sage 10.1177/1358863X19864172

Full text not available from this repository. (Request a copy)

In patients with symptomatic peripheral artery disease (PAD), the impact of chronic kidney disease (CKD) on major adverse cardiovascular events has not been fully evaluated. The Examining Use of Ticagrelor In PAD (EUCLID) trial randomized 13,885 patients with PAD to ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. This post hoc analysis compared the incidence of the primary composite endpoint (cardiovascular death, myocardial infarction (MI), or ischemic stroke) in patients with CKD (eGFR < 60 mL/min/1.73 m2) with those without CKD (eGFR ⩾ 60 mL/min/1.73 m2). The primary safety endpoint was thrombolysis in MI (TIMI) major bleeding. A total of 13,483 patients were included; 3332 (25%) had CKD, of whom 237 had stage 4/5 disease. Median follow-up was approximately 30 months. After statistical adjustment, patients with CKD had a higher rate of the primary endpoint compared with those without CKD (6.75 vs 3.72 events/100 patient-years; adjusted hazard ratio (HR) 1.45, 95% CI 1.30-1.63). CKD was not associated with increased risk of hospitalization for acute limb ischemia (ALI) (adjusted HR 0.96, 95% CI 0.69-1.34) or major amputation (adjusted HR 0.92, 95% CI 0.66-1.28). CKD was not associated with a significantly increased risk of major bleeding (adjusted HR 1.21, 95% CI 0.89-1.64), but minor bleeding was significantly increased (adjusted HR 1.51, 95% CI 1.07-2.15). In conclusion, patients with PAD and CKD had higher rates of cardiovascular death, MI, and ischemic stroke, but similar rates of ALI, major amputation, and TIMI major bleeding when compared with patients without CKD. ClinicalTrials.gov Identifier: NCT01732822.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology
UniBE Contributor:	Baumgartner, Iris
Subjects:	600 Technology > 610 Medicine & health
ISSN:	1358-863X
Publisher:	Sage
Language:	English
Submitter:	Catherine Gut
Date Deposited:	14 Jan 2020 16:01
Last Modified:	05 Dec 2022 15:32
Publisher DOI:	10.1177/1358863X19864172
PubMed ID:	31339474
Uncontrolled Keywords:	acute limb ischemia (ALI) amputation chronic kidney disease major adverse cardiovascular events major adverse limb events (MALE) major bleeding peripheral artery disease (PAD)
URI:	https://boris.unibe.ch/id/eprint/135275